# A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

> **NCT04228354** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 28 (actual)

## Conditions studied

- Healthy Volunteers
- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04228354
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-29
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04228354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04228354, "A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04228354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*